SCHEDULE: Vanguard Reports 7.51% Stake in Medtronic PLC

Vanguard Capital Management has disclosed beneficial ownership of 96,424,044 shares, representing 7.51% of Medtronic PLC's common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has filed a Schedule 13G indicating beneficial ownership of 96,424,044 shares of Medtronic PLC common stock.
• This holding represents 7.51% of the total class of securities.
• The filing specifies that Vanguard Capital Management has sole dispositive power over 96,424,044 shares and sole voting power over 13,090,211 shares.
• The reporting date for this ownership stake is March 31, 2026.
• The filing clarifies that this disclosure includes securities held by Vanguard funds and other managed accounts where Vanguard exercises dispositive and/or voting power.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant passive investment by a major institutional player, suggesting confidence in Medtronic's market position, but without providing new operational or financial performance data.

Positives

• Vanguard's significant stake suggests confidence in Medtronic's long-term prospects.
• The filing indicates a substantial investment by a major institutional investor.
• Vanguard's reporting is in accordance with standard regulatory requirements, providing transparency.

Negatives

• The filing does not contain any negative financial or operational information about Medtronic.
• No specific performance metrics or financial results are detailed in this Schedule 13G filing.

Risks

• The filing does not explicitly mention any risks related to Medtronic's business operations or financial health.
• Potential risks associated with holding a large block of shares, such as market volatility or changes in investment strategy, are not detailed.

Future Outlook

This filing is a snapshot of ownership as of March 31, 2026, and does not contain forward-looking statements or guidance from Medtronic PLC. Vanguard's future outlook on its investment is not disclosed within this document.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard typically signifies a passive investment strategy, indicating a significant but non-controlling stake. This level of ownership by a prominent asset manager often reflects a positive view of the company's stability and long-term value within the medical technology sector.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant institutional holding, which can be viewed positively by other shareholders as it indicates sustained interest from a major asset manager.
• Creditors: No direct impact on creditors is indicated by this ownership filing.
• Employees: No direct impact on employees is indicated by this ownership filing.
• Suppliers/Customers: No direct impact on suppliers or customers is indicated by this ownership filing.

Next Steps

• Vanguard Capital Management will continue to monitor its investment in Medtronic PLC.
• Future filings will be made if ownership levels change significantly or if Vanguard's investment strategy shifts to an active one.

Key Dates

Keywords

Medtronic PLC, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management